Patents by Inventor Anjelika Gasilina

Anjelika Gasilina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230129271
    Abstract: A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.
    Type: Application
    Filed: December 13, 2022
    Publication date: April 27, 2023
    Inventors: Nicolas Nassar, William Seibel, Anjelika Gasilina, Jose Cancelas
  • Compositions and methods for treating cancer
    Patent number: 11564913
    Abstract: A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: January 31, 2023
    Assignee: Children's Hospital Medical Center
    Inventors: Nicolas Nassar, William Seibel, Anjelika Gasilina, Jose Cancelas
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20200345712
    Abstract: A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.
    Type: Application
    Filed: May 1, 2020
    Publication date: November 5, 2020
    Inventors: Nicolas Nassar, William Seibel, Anjelika Gasilina, Jose Cancelas